Combined with cancer mutations in the Smad4-MH2 domain (Figure 1j and k), our data demonstrate that cancer patients can have genetic mutations or alterations that compromise the Arl15-Smad4 interaction and suggest that such genetic changes might contribute to tumorigenesis by down-regulating the TGFβ signaling pathway. The gene discussed is ARL15; the disease is cancer.